**UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549****SCHEDULE 13D  Under the Securities Exchange Act of 1934  (Amendment No. 5)***  MFIC CORPORATION  (Name of Issuer)

  Common Stock, par value $0.01 per share  (Title of Class of Securities)

  595073 10 7  (CUSIP Number)

Margaret M. Foran  Senior Vice President - Corporate Governance,   Associate General Counsel & Secretary  Pfizer Inc.  235 East 42nd Street  New York, New York 10017  212-733-4802

(Name, Address and Telephone Number of Person   Authorized to Receive Notices and Communications)

January 27, 2006

(Date of Event which Requires Filing of this Statement)

  If the filing person has previously filed a statement on Schedule 13G to report  the acquisition that is the subject of this Schedule 13D, and is filing this  schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g),  check the following box. |_|

* The remainder of this cover page shall be filled out for a reporting  person’s initial filing on this form with respect to the subject class  of securities, and for any subsequent amendment containing information which  would alter disclosures provided in a prior cover page. 

The information required on the remainder of this cover page shall not be deemed  to be "filed" for the purpose of Section 18 of the Securities Exchange  Act of 1934 ("Act") or otherwise subject to the liabilities of that  section of the Act but shall be subject to all other provisions of the Act (however,  see the Notes).

CUSIP No. 595073 10 7  1. Names of Reporting Persons I.R.S. Identification Nos. of above persons (entities  only)  G. D. Searle LLC 36-3399885  G. D. Searle LLC is an indirect wholly owned subsidiary of Pfizer Inc.  2. Check the Appropriate Box if a Member of a Group (See Instructions)  (a)   (b)   3. SEC Use Only ........................................................................................    4. Source of Funds (See Instructions) WC

  5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d)  or 2(e)   6. Citizenship or Place of Organization Delaware

 

| NUMBER OF          SHARES          BENEFICIALLY 

OWNED BY EACH REPORTING

 PERSON WITH  | 7. Sole Voting Power -0- |
|------------------------------------------------------------------------------------------|--------------------------|
| 8. Shared Voting Power   423,600 as      of 1/27/2006; 0 as of 2/15/2007       |
| 9. Sole Dispositive Power -0-                                                            |
| 10. Shared Dispositive Power   423,600      as of 1/27/2006; 0 as of 2/15/2007 |

11. Aggregate Amount Beneficially Owned by Each Reporting Person    423,600 as of 1/27/2006; 0 as of 2/15/2007   12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    13. Percent of Class Represented by Amount in Row (11)   4.3% as of  1/27/2006; 0% as of 2/15/2007  14. Type of Reporting Person (See Instructions) CO

 

**UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, DC 20549****SCHEDULE 13D  Under the Securities Exchange Act of 1934  (Amendment No. 5)***  MFIC CORPORATION  (Name of Issuer)

  Common Stock, par value $0.01 per share  (Title of Class of Securities)

  595073 10 7  (CUSIP Number)

Margaret M. Foran  Senior Vice President - Corporate Governance,   Associate General Counsel & Secretary  Pfizer Inc.  235 East 42nd Street  New York, New York 10017  212-733-4802

(Name, Address and Telephone Number of Person   Authorized to Receive Notices and Communications)

January 27, 2006

(Date of Event which Requires Filing of this Statement)

  If the filing person has previously filed a statement on Schedule 13G to report  the acquisition that is the subject of this Schedule 13D, and is filing this  schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g),  check the following box. |_|

* The remainder of this cover page shall be filled out for a reporting  person’s initial filing on this form with respect to the subject class  of securities, and for any subsequent amendment containing information which  would alter disclosures provided in a prior cover page. 

The information required on the remainder of this cover page shall not be deemed  to be "filed" for the purpose of Section 18 of the Securities Exchange  Act of 1934 ("Act") or otherwise subject to the liabilities of that  section of the Act but shall be subject to all other provisions of the Act (however,  see the Notes).

 

CUSIP No. 595073 10 7  1. Names of Reporting Persons IRS Identification Nos. of above persons (entities  only)  Pfizer Inc.  13-5315170  2. Check the Appropriate Box if a Member of a Group (See Instructions)  (a)   (b)   3. SEC Use Only ........................................................................................    4. Source of Funds (See Instructions)   WC  5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d)  or 2(e)   6. Citizenship or Place of Organization Delaware

 

| NUMBER OF          SHARES          BENEFICIALLY 

OWNED BY EACH REPORTING

 PERSON WITH  | 7. Sole Voting Power    -0- |
|------------------------------------------------------------------------------------------|--------------------------------------------|
| 8. Shared Voting Power   423,600 as      of 1/27/2006; 0 as of 2/15/2007       |
| 9. Sole Dispositive Power -0-                                                            |
| 10. Shared Dispositive Power   423,600      as of 1/27/2006; 0 as of 2/15/2007 |

11. Aggregate Amount Beneficially Owned by Each Reporting Person  423,600  as of 1/27/2006; 0 as of 2/15/2007  12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    13. Percent of Class Represented by Amount in Row (11)   4.3% as of  1/27/2006; 0% as of 2/15/2007  14. Type of Reporting Person (See Instructions) CO

  Item 5(e) of the Schedule 13 D/A is amended as follows:  Item 5. Interest in Securities of the Issuer

> 
    (e) 4.3% as of 1/27/2006; 0% as of 2/15/2007

 

 

***Signature***

  After reasonable inquiry and to the best of my knowledge and belief, I certify  that the information set forth in this statement is true, complete and correct.  September 11, 2007  Date 

Signature: /s/ Susan Grant  Susan Grant, Secretary of G. D. Searle LLC

Signature: /s/ Lawrence A. Fox  Lawrence A. Fox, Vice President, Assistant General Counsel & Assistant Secretary,  Pfizer Inc.   Name/Title 

**Attention: Intentional misstatements or omissions of fact  Constitute Federal criminal violations (See 18 U.S.C. 1001)**